Sanofi Pasteur, the vaccines division of Sanofi , today announced topline results of a large-scale, multi-center efficacy trial in people 65 years of age and older showing a superior clinical benefit of FluzoneA High-Dose relative to the standard dose of Fluzone vaccine in preventing influenza.
http://www.drugs.com/news/sanofi-fluzone-more-effective-than-standard-seniors-46960.html?
http://www.drugs.com/news/sanofi-fluzone-more-effective-than-standard-seniors-46960.html?
No comments:
Post a Comment